Drug Profile
AZD 9139
Alternative Names: AZD9139Latest Information Update: 22 Feb 2005
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Gastrokinetics
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gastro-oesophageal reflux
Most Recent Events
- 27 Jan 2005 Discontinued - Preclinical for Gastro-oesophageal reflux in Europe (unspecified route)
- 20 Oct 2004 Preclinical trials in Gastro-oesophageal reflux in Europe (unspecified route)